Results 51 to 60 of about 53,742 (236)

6th Golden Helix Pharmacogenomics Day: pharmacogenomics and individualized therapy

Human Genomics, 2012
The Golden Helix Pharmacogenomics Days are international scientific meetings aiming to educate healthcare professionals and biomedical scientists about pharmacogenomics and personalized medicine.
Stojiljkovic Maja, Fazlagic Amira, Dokmanovic-Krivokapic Lidija, Nikcevic Gordana, Patrinos George P, Pavlovic Sonja, Zukic Branka   +6 more
doaj   +1 more source

Pharmacogenomics and gemcitabine

Annals of Oncology, 2006
Approximately half of lung cancer patients present with metastases, and a large proportion will develop recurrent disease, with median survival to cisplatin-based chemotherapy of 11 months. No predictive factor of response to cisplatin-based chemotherapy is yet available in clinical practice.
Carlos Camps, B. Massuti, Dolores Isla, Manuel Cobo, Rafael Rosell   +4 more
openaire   +2 more sources

Lamivudine and tenofovir pharmacokinetic variability in people with HIV in Papua New Guinea

British Journal of Clinical Pharmacology, EarlyView.
Aims Demographics and kidney function contribute to variability in lamivudine and tenofovir drug concentrations. The aim was to assess, for the first time, the pharmacokinetic variability of lamivudine and tenofovir in Papua New Guinean (PNG) HIV/AIDS patients.
Natália Bordin Andriguetti, Daniel Thomas Barratt, Joseph Tucci, Paul Pumuye, Andrew Alexander Somogyi   +4 more
wiley   +1 more source

The needs and gaps in pharmacogenomics knowledge and education among healthcare professionals in Malaysia: A multisite Delphi study

Clinical and Translational Science
Lack of pharmacogenomics knowledge among healthcare professionals is the most significant cited barrier to implementing pharmacogenomics in clinical settings.
Safa Omran, Siew Lian Leong, Ali Blebil, Devi Mohan, Wei Chern Ang, Siew Li Teoh   +5 more
doaj   +1 more source

Knowledge, Perception, and Application of Pharmacogenomics Among Hospital Pharmacists in Saudi Arabia

Risk Management and Healthcare Policy, 2020
Mohammed Algahtani Department of Pharmaceutics, College of Pharmacy, Najran University, Najran, Kingdom of Saudi ArabiaCorrespondence: Mohammed Algahtani Email msalqahtane@nu.edu.saIntroduction: The accelerated transformation in the healthcare system ...
Algahtani M
doaj  

Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy. [PDF]

, 2011
Our study shows that in Indonesian cancer patients treated with highly cytostatic emetogenic, carriership of the CTG haplotype of the ABCB1 gene is related to an increased risk of delayed chemotherapy-induced nausea and ...
Baak-Pablo, Renee F, Gelderblom, Hans, Guchelaar, Henk-Jan, Hakimi, Mohammad, Mustofa, Mustofa, Nortier, Johann W R, Perwitasari, Dyah A, van der Straaten, Robert J H M, Wessels, Judith A M   +8 more
core   +2 more sources

Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5‐year perspective from an EQA provider

British Journal of Clinical Pharmacology, EarlyView.
Aims Pharmacogenetic implementation requires awareness of the state‐of‐the‐art practice of laboratories providing pharmacogenetic testing. This study investigated how pharmacogenetic guidelines and recommendations have been implemented over time by Italian laboratories participating in the external quality assessment (EQA) Pharmaco‐scheme established ...
Rossana Roncato, Samantha Perfler, Diletta Pasin, Elena Peruzzi, Michael Woodcock, Henry Thomas, Rebecca Goodall, Simon J. Patton, Erika Cecchin   +8 more
wiley   +1 more source

Implementing health economics for pharmacogenomics research translation in Africa

Communications Medicine
Pharmacogenomics studies how a person’s inherited genes influence response to therapeutic drugs. Many drugs do not work in all patients and pharmacogenomics can assist in the identification of patients who are better suited to particular drugs or ...
Mohamed Zahir Alimohamed, George Dennis Obeng, Marcell Csanadi, Collen Masimirembwa, Collet Dandara   +4 more
doaj   +1 more source

Pharmacogenetics of ophthalmic topical β-blockers [PDF]

, 2008
Glaucoma is the second leading cause of blindness worldwide. The primary glaucoma risk factor is elevated intraocular pressure. Topical β-blockers are affordable and widely used to lower intraocular pressure.
McCarty, Catherine A., Patchett, Richard, Sidjanin, Duska J., Smith, Edward M., Wilke, Russell A.   +4 more
core   +1 more source

Pharmacogenomics in clinical practice: Biomarker information in Brazilian drug labels

British Journal of Clinical Pharmacology, EarlyView.
This review examines the PGx annotations in package inserts (bulas in Brazilian Portuguese) approved by ANVISA, the Brazilian Health Regulatory Agency, for 19 gene–drug pairs with strong or moderate recommendations for initial dosing alteration in the CPIC (Clinical Pharmacogenetic Implementation Consortion) guidelines and PGx testing required or ...
Guilherme Suarez‐Kurtz
wiley   +1 more source